Combined treatment of miltefosine and paromomycin delays the onset of experimental drug resistance in Leishmania infantum

Laboratory confirmed miltefosine resistant cases of visceral leishmaniasis from India

(2017) Saumya Srivastava et al.   Parasites & Vectors

Different Mutations in a P-type ATPase Transporter in Leishmania Parasites are Associated with Cross-resistance to Two Leading Drugs by Distinct Mechanisms

(2016) Christopher Fernandez-Prada et al.   PLoS Neglected Tropical Diseases

In VivoSelection of Paromomycin and Miltefosine Resistance in Leishmania donovani and L. infantum in a Syrian Hamster Model

(2015) S. Hendrickx et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Intracellular amastigote replication may not be required for successful in vitro selection of miltefosine resistance in Leishmania infantum

(2015) S. Hendrickx et al.   PARASITOLOGY RESEARCH

Elucidation of Cellular Mechanisms Involved in Experimental Paromomycin Resistance in Leishmania donovani

(2014) V. Bhandari et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

The in vitro leishmanicidal activity of hexadecylphosphocholine (miltefosine) against four medically relevant Leishmania species of Brazil

(2014) Eliane de Morais-Teixeira et al.   MEMORIAS DO INSTITUTO OSWALDO CRUZ

Experimental selection of paromomycin and miltefosine resistance in intracellular amastigotes of Leishmania donovani and L. infantum

(2014) S. Hendrickx et al.   PARASITOLOGY RESEARCH

Miltefosine and Antimonial Drug Susceptibility of Leishmania Viannia Species and Populations in Regions of High Transmission in Colombia

(2014) Olga Lucía Fernández et al.   PLoS Neglected Tropical Diseases

In Vitro and In Vivo Miltefosine Susceptibility of a Leishmania amazonensis Isolate from a Patient with Diffuse Cutaneous Leishmaniasis

(2014) Adriano C. Coelho et al.   PLoS Neglected Tropical Diseases

Epidemiology of visceral leishmaniasis

(2014) Paul Ready   Clinical Epidemiology

Treatment Failure and Miltefosine Susceptibility in Dermal Leishmaniasis Caused by Leishmania Subgenus Viannia Species

(2013) Ricardo Obonaga et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Increasing Failure of Miltefosine in the Treatment of Kala-azar in Nepal and the Potential Role of Parasite Drug Resistance, Reinfection, or Noncompliance

(2013) Suman Rijal et al.   CLINICAL INFECTIOUS DISEASES

Therapeutic Options for Visceral Leishmaniasis

(2013) Begoña Monge-Maillo et al.   DRUGS

Efficacy and safety of single-dose liposomal amphotericin B for visceral leishmaniasis in a rural public hospital in Bangladesh: a feasibility study

(2013) Dinesh Mondal et al.   Lancet Global Health

Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis

(2012) T. P. C. Dorlo et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Experimental Induction of Paromomycin Resistance in Antimony-Resistant Strains of L. donovani: Outcome Dependent on In Vitro Selection Protocol

(2012) Sarah Hendrickx et al.   PLoS Neglected Tropical Diseases

Mechanism of Amphotericin B Resistance in Clinical Isolates of Leishmania donovani

(2011) Bidyut Purkait et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial

(2011) Shyam Sundar et al.   LANCET

Immunomodulatory effect of picroliv on the efficacy of paromomycin and miltefosine in combination in experimental visceral leishmaniasis

(2010) Shraddha A. Sane et al.   EXPERIMENTAL PARASITOLOGY

Single-Dose Liposomal Amphotericin B for Visceral Leishmaniasis in India

(2010) Shyam Sundar et al.   NEW ENGLAND JOURNAL OF MEDICINE

In Vitro Susceptibilities of Leishmania donovani Promastigote and Amastigote Stages to Antileishmanial Reference Drugs: Practical Relevance of Stage-Specific Differences

(2009) M. Vermeersch et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY